Catalio leads $36M into ZAP Surgical as brain radiosurgery moves into community hospitals

ZAP Surgical Systems has raised $36M in a financing led by Catalio Capital Management, with continued support from Baheal, the company's strategic partner in China. The San Carlos, California-based manufacturer said the capital will support production and global deployment of ZAP-X, its dedicated cranial radiosurgery platform.

The announcement, made October 19, 2026, deliberately leaves the deal's architecture open: ZAP discloses no series label, no valuation and no financing instrument. That distinguishes it from the company's $78M Series E in November 2024, led by Qingdao Baheal Medical — a round that belongs to ZAP's history and does not establish terms for the current raise.

The technology at the center of the raise is a linear accelerator mounted on a gyroscopic system with built-in self-shielding. ZAP describes a platform capable of more than 1,000 non-coplanar beam angles, a delivery-flexibility specification rather than a claim of superior outcomes. Because the beam is generated without radioactive cobalt sources that require management and eventual replacement, and because self-shielding can eliminate the need for a dedicated radiation vault under typical usage — country shielding rules vary — the equipment and the room it sits in become a single purchasing decision.

That is the commercial argument ZAP is scaling. The company reports it recently shipped its 50th ZAP-X system and that nearly 10,000 patients have been treated worldwide. FDA clearance records for an earlier ZAP-X system name CyberKnife M6 as a reference device and describe treatment planning, image-guided stereotactic radiosurgery and precision radiotherapy for indicated tumors, lesions and conditions of the brain, head and neck — language that keeps the pitch tied to cleared uses.

The clearest illustration of the thesis sits in Fukuoka, Japan. Fukuoka Kieikai Hospital, a 260-bed community institution, currently refers its cranial radiosurgery patients to other facilities. Its planned ZAP-X program, announced October 1, would serve Fukuoka Prefecture and the wider Kyushu region, with installation expected to begin in October and first treatments anticipated in early 2027. The machine is slated for a glass-walled, first-floor corner formerly occupied by a retail business — a specialized clinical capability placed inside the ordinary footprint of a community hospital. Those benefits remain prospective until the program opens.

A second site, announced in September with GenesisCare at St Vincent's Hospital in Sydney, anticipated installation in fall 2026 and first treatments before year-end.

Catalio's involvement comes with a named observer: principal Nicholas von Guionneau, who has a background in clinical medicine and research on nerve regeneration and implantable neurodevices, joins ZAP's board as an observer.